High-Grade Poorly Differentiated Gastric Adenocarcinoma: When a Chest Radiograph Reveals an Unexpected Gastric Cancer
Executive Clinical Summary
A 90-year-old man presented with progressive bilateral leg edema for one month, accompanied by repeated episodes of malaise and dizziness associated with hypoglycemia. Physical examination revealed a nontender epigastric mass.
The initial chest radiograph unexpectedly demonstrated a round, irregular opacity projected within the gastric chamber. An unusual colonic segment was also visible beneath the right hemidiaphragm. Subsequent upper gastrointestinal endoscopy revealed a large, extensively eroded exophytic mass in the subcardial region of the stomach. Histologic examination was consistent with high-grade poorly differentiated gastric adenocarcinoma.
The patient was diagnosed with advanced gastric cancer and received palliative treatment. He died five months later.
This case illustrates an important radiologic principle: an abnormality outside the primary field of interest may be the first imaging clue to a clinically significant malignancy. A chest radiograph is not designed to stage gastric cancer, yet the lower portion of the image may include clinically meaningful information about the upper abdomen.
The case also provides an opportunity to examine how the radiologist should proceed when an unexpected gastric abnormality is seen, how CT, endoscopy, EUS, MRI, and PET/CT contribute to staging, and how emerging artificial intelligence technologies may eventually assist in detection and risk stratification.
Key Clinical Questions
What can a gastric malignancy look like on a chest radiograph?
Why can a large gastric tumor project as an abnormal opacity within the gastric air bubble?
What does poorly differentiated and high-grade mean histologically?
How should gastric adenocarcinoma be evaluated after an unexpected radiographic finding?
What are the complementary roles of endoscopy, EUS, contrast-enhanced CT, MRI, and PET/CT?
Which imaging findings suggest locally advanced disease?
Why can peritoneal metastasis remain difficult to detect on CT?
How might radiomics and AI contribute to gastric cancer imaging?
Where can AI-assisted gastric cancer interpretation fail?
Introduction
Gastric adenocarcinoma is primarily evaluated with endoscopy and cross-sectional imaging. Nevertheless, clinically important abnormalities can occasionally appear on examinations performed for an entirely different reason.
This case is particularly instructive because the first imaging clue was found on a chest radiograph rather than on a dedicated abdominal examination.
A 90-year-old man presented with progressive bilateral lower-extremity edema, malaise, and dizziness associated with hypoglycemia. A physical examination revealed a palpable, nontender epigastric mass. The chest radiograph showed a round, irregular opacity within the gastric chamber. Subsequent endoscopy identified an extensively eroded exophytic mass in the subcardial stomach, and biopsy demonstrated high-grade poorly differentiated gastric adenocarcinoma.
The clinical lesson extends beyond this individual case.
Radiologists frequently review examinations in which the primary target organ is not the stomach. However, the lower chest radiograph includes portions of the upper abdomen, and unexpected abnormalities in this region should not automatically be dismissed as incidental.
In this setting, recognizing the abnormality is only the first step. The next question is whether the finding represents an intragastric mass, an extrinsic process, altered gastric anatomy, or an artifact. Once a true gastric lesion is suspected, definitive evaluation requires endoscopy and tissue diagnosis, followed by appropriate staging.
Clinical Hook: The Gastric Lesion Hidden at the Bottom of a Chest Radiograph
The most important image in this case was not obtained specifically to diagnose gastric cancer.
The chest radiograph demonstrated a round, irregular opacity projected within the gastric chamber. The finding was unusual enough to prompt additional evaluation.
This is an important reminder about radiographic interpretation.
A chest radiograph should be interpreted as a complete examination rather than as a narrowly defined search for pulmonary disease. The diaphragm, upper abdomen, gastric air bubble, osseous structures, soft tissues, and visible bowel may contain diagnostically important information.
In the present case, the gastric abnormality became the gateway to the diagnosis of an advanced gastric malignancy.
Learning Objectives
By the end of this article, readers should be able to:
Recognize an unexpected gastric abnormality on a chest radiograph.
Understand the clinical significance of high-grade poorly differentiated gastric adenocarcinoma.
Describe the complementary roles of endoscopy, CT, EUS, MRI, and PET/CT in gastric cancer evaluation.
Identify imaging features associated with locally advanced gastric cancer.
Understand important differential diagnoses for an intragastric or projected gastric opacity.
Recognize limitations of CT and other imaging modalities in detecting small-volume peritoneal disease.
Understand realistic applications and limitations of AI in gastric cancer imaging.
Case Presentation
Patient Profile
Age: 90 years
Sex: Male
Presenting Symptoms
The patient presented with:
Progressive bilateral leg edema for one month
Repeated episodes of malaise
Dizziness associated with hypoglycemia
Physical Examination
A nontender epigastric mass was palpated.
Initial Imaging
A chest radiograph demonstrated a round, irregular opacity within the gastric chamber. A portion of the colon was also visible beneath the right hemidiaphragm.
Figure 1. Frontal chest radiograph demonstrating an abnormal opacity within the gastric chamber.
Radiologist Interpretation:
The frontal chest radiograph demonstrates a round, irregular soft-tissue opacity projected within the left upper abdomen and gastric air bubble. The opacity has a relatively well-defined rounded contour with heterogeneous internal density. The finding is located in the expected region of the stomach rather than within the thoracic cavity. A portion of the colon is also projected beneath the right hemidiaphragm.
In the clinical context of this case, the gastric-region opacity represents an important abnormal finding that prompted further gastrointestinal evaluation. However, a chest radiograph alone cannot establish the histologic nature or exact anatomical origin of the lesion. Further evaluation with upper gastrointestinal endoscopy and cross-sectional imaging is therefore required.
Clinical Significance:
The key diagnostic point is that an abnormality within the gastric air bubble may be visible incidentally on a chest radiograph obtained for another clinical indication. In this patient, the unexpected gastric opacity led to endoscopic evaluation, which demonstrated an extensively eroded exophytic subcardial gastric mass subsequently diagnosed histologically as high-grade poorly differentiated gastric adenocarcinoma.
ALT Text:
Frontal chest radiograph showing a round irregular opacity projected within the gastric air bubble in a patient subsequently diagnosed with high-grade poorly differentiated gastric adenocarcinoma.
Endoscopic Findings
Upper gastrointestinal endoscopy revealed an extensively eroded exophytic mass in the subcardial region.
Pathology
Histologic examination was consistent with:
High-grade poorly differentiated gastric adenocarcinoma.
Final Diagnosis
Advanced gastric cancer caused by high-grade poorly differentiated gastric adenocarcinoma.
Treatment and Outcome
The patient received treatment directed toward symptom palliation. He died five months after presentation.
What Is High-Grade Poorly Differentiated Gastric Adenocarcinoma?
Gastric adenocarcinoma arises from epithelial cells of the stomach and represents the dominant histologic category of gastric malignancy.
The terms high-grade and poorly differentiated describe biological and microscopic characteristics rather than simply tumor size.
A poorly differentiated tumor contains malignant cells that have lost many of the architectural and cytologic characteristics of normal gastric glandular epithelium. The tumor therefore may have a more disorganized appearance and may demonstrate aggressive biological behavior.
The designation high-grade indicates marked cytologic atypia and a high degree of abnormal cellular proliferation compared with lower-grade tumors.
Importantly, histologic grade should not be interpreted in isolation. Clinical behavior and prognosis are influenced by multiple factors, including:
Depth of invasion
Regional lymph-node involvement
Distant metastasis
Peritoneal dissemination
Histologic subtype
Molecular characteristics
Patient age and physiological reserve
Response to treatment
Therefore, the radiologist should avoid translating "poorly differentiated" directly into a specific TNM stage. Histologic grade and anatomic stage answer different clinical questions.
Why the Chest Radiograph Matters
The chest radiograph in this case showed a round, irregular opacity in the gastric chamber.
This finding is not pathognomonic for gastric carcinoma.
Potential explanations for a rounded opacity projected over the gastric air bubble include:
| Differential Diagnosis | Possible Radiographic Appearance | Key Differentiating Point |
|---|---|---|
| Gastric carcinoma | Irregular soft-tissue opacity | Requires endoscopic and pathologic confirmation |
| Gastric bezoar | Intraluminal mottled mass | Internal gas pattern may be present |
| Gastric polyp or mass | Rounded filling or soft-tissue opacity | Usually requires endoscopy |
| Gastric distention or food material | Variable intragastric opacity | Clinical and radiographic context |
| Extrinsic mass | Apparent gastric-region opacity | CT can demonstrate the anatomical origin |
| Gastric ulcer-related inflammatory process | Focal abnormality | Endoscopic correlation required |
| Artifact or overlapping structure | Projected opacity | Cross-sectional imaging clarifies origin |
The key principle is that projectional imaging cannot reliably establish the organ of origin of a complex upper abdominal mass.
When a suspicious opacity is seen within the gastric air bubble, the appropriate response is not to assign a definitive histologic diagnosis from the radiograph. Instead, the finding should trigger correlation with the clinical history and dedicated gastrointestinal evaluation.
The Anatomical Perspective
The stomach occupies the upper abdomen beneath the left hemidiaphragm and extends across the upper abdominal midline.
The subcardial region lies immediately below the gastroesophageal junction. Its location is clinically important because tumors arising here may have relationships with:
The distal esophagus
Gastric cardia
Lesser curvature
Left hepatic lobe
Pancreas
Transverse colon
Perigastric lymph-node stations
Perigastric vessels
A large exophytic tumor may therefore extend beyond the expected gastric contour.
This is one reason why cross-sectional imaging becomes essential after endoscopic detection of an advanced gastric lesion.
Imaging Features of Gastric Adenocarcinoma
Endoscopy
Endoscopy remains fundamental because it permits direct visualization of the mucosal surface and tissue sampling.
In this case, the lesion was described as an extensively eroded exophytic mass in the subcardial region. Histologic examination subsequently established the diagnosis of high-grade poorly differentiated adenocarcinoma.
Endoscopy provides information about:
Tumor location
Mucosal ulceration
Surface morphology
Circumferential involvement
Luminal narrowing
Bleeding
Relationship to the gastroesophageal junction
However, endoscopy alone cannot fully characterize extramural extension or distant metastatic disease.
CT: The Central Cross-Sectional Imaging Examination
Contrast-enhanced multidetector CT plays a central role in the staging of gastric cancer.
The CT examination should be interpreted systematically.
Important features include:
Tumor location
Gastric wall thickening
Enhancement pattern
Tumor morphology
Loss of normal wall-layer architecture
Perigastric fat infiltration
Serosal irregularity
Adjacent-organ involvement
Regional lymphadenopathy
Liver metastases
Peritoneal nodules
Ascites
Distant metastatic disease
Contemporary imaging literature supports an important role for CT not only in metastatic assessment but also in locoregional staging.
CT-Based T-Staging: What the Radiologist Looks For
The distinction between T categories is fundamentally an assessment of how deeply the tumor has penetrated the gastric wall and whether it has extended beyond the stomach.
| T Stage | Pathologic Concept | Typical CT Considerations |
|---|---|---|
| T1 | Mucosa/submucosa involvement | Focal or subtle wall abnormality; early lesions may be difficult to detect |
| T2 | Muscularis propria involvement | Wall thickening with relatively preserved outer contour |
| T3 | Subserosal invasion | Extension toward or into perigastric tissues without definite serosal penetration |
| T4a | Serosal involvement | Irregular outer gastric contour and perigastric inflammatory or nodular changes |
| T4b | Adjacent-organ invasion | Loss of fat plane with convincing invasion of adjacent structures |
Figure 2. CT examples of T2 gastric cancer demonstrating enhancing gastric wall thickening with invasion of the muscularis propria.
Radiologist Interpretation:
The CT examples demonstrate focal enhancing gastric wall thickening involving the muscularis propria without imaging evidence of extension through the serosal surface. The examples illustrate the cross-sectional appearance of T2 gastric cancer and the importance of evaluating the thickness and outer contour of the gastric wall.
Clinical Significance:
Recognition of the depth of gastric wall involvement is fundamental to local tumor staging. CT assessment should be correlated with endoscopy and, when appropriate, EUS.
Source: Adapted from Giandola et al., Diagnostics, 2023;13:1276.
ALT Text:
CT examples demonstrating gastric wall thickening in T2 gastric cancer with muscularis propria involvement.
Figure 3. CT examples of T3 gastric cancer demonstrating tumor extension into the subserosal layer.
Radiologist Interpretation:
The CT images demonstrate irregular enhancing gastric wall thickening extending beyond the muscularis propria toward the subserosal tissue. The outer gastric contour remains without definite direct invasion of adjacent organs.
The accompanying example also demonstrates a cluster of pathological lymph nodes adjacent to the gastric tumor.
Clinical Significance:
The distinction between T3 disease and more advanced serosal or adjacent-organ invasion is clinically important. Evaluation of the outer gastric contour and perigastric fat should therefore be systematic.
Source: Adapted from Giandola et al., Diagnostics, 2023;13:1276.
ALT Text:
Contrast-enhanced CT demonstrating T3 gastric cancer with subserosal extension and adjacent pathological lymph nodes.
Figure 4. CT examples of T4a gastric cancer with serosal involvement and perigastric abnormalities.
Radiologist Interpretation:
The CT examples demonstrate irregular enhancing gastric wall thickening extending through the gastric wall to involve the serosal surface. Associated perigastric soft-tissue changes and pathological lymph nodes are present. One example demonstrates irregularity and nodular changes within the surrounding perigastric fat.
Clinical Significance:
T4a disease represents serosal involvement. However, perigastric inflammatory change and desmoplastic reaction may mimic tumor extension. The radiologist should therefore avoid overcalling T4a disease based solely on nonspecific fat stranding.
Source: Adapted from Giandola et al., Diagnostics, 2023;13:1276.
ALT Text:
Contrast-enhanced CT examples showing T4a gastric cancer with serosal involvement and pathological perigastric changes.
Figure 5. CT example of T4b gastric cancer demonstrating invasion of an adjacent organ.
Radiologist Interpretation:
The CT images demonstrate a bulky gastric tumor with heterogeneous internal components, ulcerative change, and extension into the surrounding tissues. The tumor extends directly into the transverse colon, with imaging evidence of fistulous communication.
Clinical Significance:
Direct invasion of an adjacent organ represents T4b disease. Recognition of the anatomical relationship between the primary gastric tumor and neighboring organs is essential for staging and treatment planning.
Source: Adapted from Giandola et al., Diagnostics, 2023;13:1276.
ALT Text:
Contrast-enhanced CT demonstrating bulky T4b gastric cancer with direct invasion of the transverse colon.
These findings must be interpreted cautiously because inflammatory change and desmoplastic reaction can mimic tumor extension.
For example, linear stranding in perigastric fat does not automatically establish T4 disease. The distinction between T3 and T4a may be particularly difficult.
The published imaging review emphasizes that CT assessment of serosal invasion can be challenging because the gastric serosa may not be clearly visualized, while solid nodules or irregular band-like changes in perigastric fat may support serosal involvement.
Regional Lymph Nodes
Regional lymph-node assessment is an essential component of staging.
Suspicious nodes may demonstrate:
Enlarged short-axis diameter
Rounded morphology
Abnormal enhancement
Clustering
Necrosis in some advanced cases
Anatomical distribution compatible with regional drainage
However, size alone cannot reliably distinguish reactive from metastatic nodes.
Therefore, the radiologist should integrate:
size + morphology + distribution + primary tumor characteristics + clinical context.
This is especially important in poorly differentiated tumors, where the possibility of aggressive nodal disease may influence the overall staging strategy.
Peritoneal Disease: A Major Imaging Challenge
Peritoneal carcinomatosis is one of the most clinically important forms of metastatic gastric cancer.
CT is widely used for peritoneal evaluation, but sensitivity decreases for very small implants.
Small-volume peritoneal deposits may be difficult to detect when they are:
Less than several millimeters
Adjacent to bowel loops
Along the mesentery
Near the diaphragmatic surfaces
Subtle against surrounding soft tissues
Associated with little or no ascites
The 2023 imaging review reports substantial variability in CT sensitivity for peritoneal carcinomatosis and emphasizes particularly limited detection of very small lesions.
Consequently, a negative CT examination does not necessarily exclude microscopic or low-volume peritoneal disease.
This is one of the reasons why imaging findings must be integrated with surgical, endoscopic, pathological, and multidisciplinary information.
EUS: High-Resolution Assessment of the Gastric Wall
Endoscopic ultrasonography provides high-resolution visualization of the gastric wall layers.
Its major strength is the ability to assess the depth of tumor penetration through the gastric wall.
EUS may be particularly useful when the clinical question concerns early or localized disease.
However, EUS has limitations:
Operator dependence
Limited field of view
Limited penetration depth
Difficulty evaluating some gastric regions
Difficulty with very large or extensively ulcerated tumors
Limited assessment of distant metastases
The subcardial location is itself relevant because this region can be technically challenging for complete evaluation.
MRI: A Complementary Imaging Tool
MRI offers excellent soft-tissue contrast and can provide multiparametric information.
Potentially useful sequences include:
T2-weighted imaging
T1-weighted imaging
Fat-suppressed post-contrast imaging
Diffusion-weighted imaging
Apparent diffusion coefficient mapping
MRI can be particularly valuable when characterization of liver lesions or peritoneal disease is clinically important.
However, MRI is not simply a replacement for CT.
Its practical limitations include:
Longer examination time
Motion sensitivity
Patient tolerance
Availability
Protocol variability
The current literature describes MRI as a promising complementary modality rather than a universal replacement for established staging pathways.
PET/CT: Metabolic Information With Important Limitations
FDG PET/CT may contribute metabolic information in selected gastric cancer patients.
However, gastric cancers do not all demonstrate identical FDG avidity.
This is clinically important because a relatively low FDG signal does not necessarily exclude malignancy.
PET/CT may contribute to:
Identification of metabolically active disease
Assessment of selected lymph nodes
Detection of distant disease
Treatment-response assessment in selected contexts
Its role should therefore be determined according to tumor biology, clinical scenario, and the intended staging question rather than used automatically for every patient.
Multimodal Imaging Comparison
| Modality | Major Strength | Important Limitation | Best Clinical Question |
|---|---|---|---|
| Endoscopy | Direct mucosal visualization and biopsy | Limited extramural assessment | Is there a mucosal tumor and can it be biopsied? |
| EUS | High-resolution wall-layer assessment | Operator-dependent and limited depth | How deeply does a localized tumor invade? |
| Contrast CT | Whole-body anatomical staging | Limited sensitivity for tiny peritoneal deposits | Is there locally advanced or metastatic disease? |
| MRI | Superior soft-tissue contrast | Longer examination and availability | Is additional soft-tissue or liver/peritoneal characterization needed? |
| PET/CT | Metabolic assessment | Variable tumor FDG avidity | Is metabolically active disease present? |
No single modality answers every clinical question.
The strength of gastric cancer imaging lies in complementarity rather than competition among modalities.
Clinical Workflow
A practical diagnostic pathway after an unexpected gastric opacity can be summarized as:
This pathway emphasizes an important principle: imaging should be selected according to the clinical question, not simply because multiple modalities are available.
Treatment
Treatment of gastric adenocarcinoma depends on disease stage, tumor characteristics, molecular findings, patient condition, and treatment goals.
Potential treatment strategies include:
Endoscopic treatment in selected early cancers
Surgical resection
Perioperative systemic therapy
Chemotherapy
Targeted therapy for appropriate molecular subgroups
Immunotherapy in selected settings
Radiation therapy in selected clinical circumstances
Palliative interventions for advanced disease
Symptom-directed supportive care
In an elderly patient with advanced disease, treatment selection also requires consideration of physiological reserve, comorbidities, functional status, treatment tolerance, and goals of care.
The present case received palliative treatment, and the patient died five months after presentation.
Prognostic Considerations
Prognosis in gastric cancer is primarily influenced by disease stage and tumor biology.
Important prognostic factors include:
Depth of invasion
Lymph-node involvement
Distant metastasis
Peritoneal dissemination
Histologic subtype
Tumor differentiation
Molecular characteristics
Response to treatment
Patient-related factors
Poor differentiation can be associated with aggressive tumor biology, but it should not be interpreted as an independent substitute for complete staging.
For an individual patient, prognosis must be determined from the total clinical, pathological, molecular, and imaging picture.
Artificial Intelligence Perspective
Gastric cancer represents an interesting target for medical AI because diagnosis and staging require integration of multiple data types.
A future gastric cancer AI platform could potentially analyze:
This multimodal architecture could potentially support:
Tumor detection
Segmentation
T-stage prediction
Lymph-node assessment
Peritoneal metastasis detection
Treatment-response prediction
Recurrence-risk modeling
Radiomics analysis
Multimodal clinical decision support
Recent literature describes growing research interest in radiomics and AI for gastric cancer detection, staging, peritoneal disease prediction, and treatment-response assessment. However, many such systems remain research technologies rather than universally validated clinical tools.
AI Workflow
A realistic clinical AI workflow could be:
The critical point is that AI should function as a clinical decision-support system rather than an autonomous replacement for the radiologist.
AI Failure Modes
A gastric cancer AI model may fail when confronted with:
Poor gastric distension
Motion artifacts
Unusual tumor morphology
Post-treatment changes
Severe inflammation
Rare histologic subtypes
Small peritoneal implants
Anatomical distortion
Unexpected adjacent-organ disease
Different CT acquisition protocols
External-domain images
Population differences
Dataset bias
A model trained primarily on large, conspicuous gastric masses may perform substantially differently when confronted with a subtle lesion or a tumor with an unusual morphology.
This is a central issue in clinical AI deployment.
High performance on a retrospective dataset does not automatically equal safe performance in routine clinical practice.
Explainable AI and Gastric Cancer
Explainability may be particularly valuable in gastric cancer imaging.
An AI system could potentially provide:
Tumor localization
Segmentation masks
Suspicious lymph-node localization
Peritoneal-lesion heat maps
Confidence estimates
Quantitative tumor volume
Longitudinal change measurements
However, a heat map should not be interpreted as proof that the AI has identified the correct pathology.
A visually convincing explanation can still be wrong.
Therefore, explainability should support verification rather than replace clinical judgment.
Enterprise Healthcare Workflow
At hospital scale, gastric cancer AI could operate within an enterprise imaging environment:
Interoperability standards such as DICOM, HL7, and FHIR can support integration, depending on the architecture of the healthcare institution.
A hospital implementation should also address:
Data governance
Cybersecurity
Audit logging
Model monitoring
Version control
Performance drift
Downtime procedures
Human oversight
Regulatory requirements
Vendor management
Future Precision Medicine
The future of gastric cancer imaging is likely to move toward integration of anatomical imaging, quantitative imaging biomarkers, pathology, molecular data, and AI.
Potential research directions include:
CT radiomics
MRI radiomics
Multimodal foundation models
Vision-language models
Radiogenomics
Digital pathology integration
Federated learning
Multimodal treatment-response prediction
Molecularly guided imaging
Personalized risk prediction
These approaches remain at different stages of development.
The distinction between research promise and established clinical practice is essential.
Expert Insights
Expert Insight 1 — Radiologist Perspective
A chest radiograph may contain clinically important findings outside the lungs. The gastric air bubble should not be ignored when an abnormal soft-tissue opacity is visible.
Expert Insight 2 — Imaging Perspective
A projected gastric opacity is a finding, not a diagnosis. Cross-sectional imaging and endoscopic evaluation are required to establish its origin and nature.
Expert Insight 3 — Pathology Perspective
"Poorly differentiated" describes cellular differentiation and architecture. It should not be confused with anatomical stage.
Expert Insight 4 — Staging Perspective
The radiologist's primary contribution after diagnosis is often to define the anatomical extent of disease: local invasion, regional nodes, peritoneal disease, and distant metastases.
Expert Insight 5 — CT Perspective
The distinction between T3 and T4a disease can be difficult because inflammatory and desmoplastic changes may mimic tumor extension.
Expert Insight 6 — Peritoneal Perspective
A negative CT examination cannot reliably exclude microscopic peritoneal disease.
Expert Insight 7 — Multimodality Perspective
Endoscopy, EUS, CT, MRI, and PET/CT answer different questions. Their value is complementary.
Expert Insight 8 — AI Perspective
The most clinically useful AI system is unlikely to be a simple "cancer/no cancer" classifier. Quantitative localization, staging support, longitudinal comparison, and workflow integration may provide greater clinical value.
Expert Insight 9 — Enterprise Perspective
An AI model that is technically accurate but poorly integrated into PACS/RIS/EMR may have limited clinical impact.
Expert Insight 10 — Governance Perspective
Every deployed model requires continuous monitoring because changes in scanners, protocols, patient populations, and clinical workflows can alter model performance.
Clinical Pearls
An unexpected gastric opacity can appear on a chest radiograph.
The gastric air bubble should be assessed on chest radiographs when visible.
A projected opacity cannot establish the organ of origin with certainty.
Endoscopy provides direct mucosal assessment and tissue diagnosis.
Poor differentiation describes tumor histology, not TNM stage.
CT plays a major role in overall staging.
EUS is particularly useful for high-resolution local wall assessment.
MRI provides excellent soft-tissue contrast and can complement CT.
PET/CT has a selective rather than universal role in gastric cancer evaluation.
Small peritoneal implants may be missed on CT.
Serosal invasion can be difficult to distinguish from perigastric inflammatory change.
Lymph-node size alone is insufficient for reliable metastatic assessment.
AI can assist detection and quantitative analysis but requires human verification.
Explainability does not guarantee AI correctness.
Clinical AI performance must be monitored after deployment.
Common Diagnostic Pitfalls
Pitfall 1: Ignoring the Gastric Air Bubble
A radiologist focused exclusively on the lungs may overlook an abnormal upper-abdominal finding.
Pitfall 2: Calling Every Gastric Opacity Cancer
An opacity projected over the stomach has a broad differential diagnosis.
Pitfall 3: Equating Poor Differentiation With Stage IV Disease
Histologic grade and TNM stage are different concepts.
Pitfall 4: Overcalling Perigastric Fat Stranding
Inflammation and desmoplastic reaction can mimic direct tumor extension.
Pitfall 5: Assuming a Negative CT Excludes Peritoneal Metastasis
Small-volume peritoneal disease can be below the detection threshold of CT.
Pitfall 6: Treating AI Output as a Final Diagnosis
AI findings must be reviewed against the actual imaging and clinical context.
Pitfall 7: Ignoring Technical Quality
Poor gastric distension, motion, inadequate contrast timing, or incomplete coverage may compromise staging.
Frequently Asked Questions
What is high-grade poorly differentiated gastric adenocarcinoma?
It is a gastric adenocarcinoma characterized histologically by marked cellular atypia and limited resemblance to normal gastric glandular tissue. It represents an aggressive histologic phenotype, but tumor grade should be interpreted separately from anatomical TNM stage.
What was the first imaging clue in this case?
The chest radiograph showed a round, irregular opacity within the gastric chamber.
How was the diagnosis established?
Upper gastrointestinal endoscopy demonstrated an extensively eroded exophytic subcardial mass, and histologic examination established high-grade poorly differentiated gastric adenocarcinoma.
Can a chest X-ray diagnose gastric cancer?
No. A chest radiograph may reveal a suspicious gastric-region abnormality, but definitive diagnosis requires appropriate gastrointestinal evaluation and pathological confirmation.
What is the role of CT?
Contrast-enhanced CT is central to assessment of local extension, regional lymph nodes, and distant metastatic disease.
What is the role of EUS?
EUS provides high-resolution visualization of the gastric wall layers and can be particularly useful for local T-stage assessment.
Is MRI useful?
MRI can provide excellent soft-tissue contrast and may be useful for selected local, liver, or peritoneal assessments, but its role should complement rather than automatically replace CT and endoscopy.
Is PET/CT required in every gastric cancer patient?
No. Its usefulness depends on tumor biology and the clinical staging question.
Can AI diagnose gastric cancer?
AI research has demonstrated potential for detection, staging, radiomics, treatment-response prediction, and peritoneal disease assessment. However, many applications remain under clinical validation and should not be treated as autonomous diagnostic systems.
Why is multidisciplinary assessment important?
Gastric cancer management requires integration of pathology, endoscopy, imaging, molecular information, surgery, oncology, and patient-specific clinical factors.
Quiz
Question 1
A chest radiograph demonstrates a round irregular opacity projected within the gastric air bubble. What is the most appropriate next interpretation?
① The finding definitively represents gastric adenocarcinoma
② The finding is always a gastric bezoar
③ The finding should be correlated clinically and evaluated with dedicated gastrointestinal assessment
④ The finding can be staged as T4 disease from the radiograph
⑤ PET/CT is mandatory before endoscopy
Correct Answer: ③
Explanation: A projected gastric opacity is not histologically diagnostic. The appropriate approach is clinical correlation followed by dedicated gastrointestinal evaluation, typically including endoscopy when clinically indicated.
Question 2
What does "poorly differentiated" primarily describe?
① Tumor size
② Distant metastasis
③ Histologic resemblance to normal tissue
④ TNM stage
⑤ Number of lymph nodes
Correct Answer: ③
Explanation: Poor differentiation describes the degree to which malignant cells and architecture resemble normal tissue.
Question 3
Which modality provides high-resolution assessment of gastric wall layers?
① Chest radiography
② EUS
③ Noncontrast head CT
④ Bone scintigraphy
⑤ Mammography
Correct Answer: ②
Explanation: EUS provides high-resolution imaging of the gastric wall and is particularly useful for local tumor-depth assessment.
Question 4
Which is a major limitation of CT in gastric cancer staging?
① CT cannot demonstrate lymph nodes
② CT cannot demonstrate the stomach
③ Small-volume peritoneal metastases may be difficult to detect
④ CT cannot evaluate distant organs
⑤ CT cannot demonstrate tumor enhancement
Correct Answer: ③
Explanation: CT is central to staging but has limited sensitivity for very small peritoneal deposits.
Question 5
Which statement best describes clinical AI in gastric cancer?
① AI should replace radiologists
② A retrospective AUC automatically proves clinical safety
③ Heat maps guarantee correct diagnosis
④ AI may support detection, staging, and quantitative analysis but requires clinical validation and human oversight
⑤ AI eliminates the need for pathology
Correct Answer: ④
Explanation: AI can augment imaging interpretation, but clinical deployment requires validation, monitoring, governance, and human oversight.
Conclusion
This case demonstrates how an important gastric malignancy can first become visible on an examination that was not primarily intended to evaluate the stomach.
A round, irregular opacity within the gastric chamber on a chest radiograph led to further evaluation, revealing an extensively eroded exophytic subcardial mass. Histology established high-grade poorly differentiated gastric adenocarcinoma.
The broader lesson is not simply that gastric cancer can appear on a chest radiograph.
It is that radiologic diagnosis begins with recognizing an abnormality and continues with asking the right clinical question.
For gastric cancer, no single imaging technique provides every answer. Endoscopy establishes mucosal pathology and permits biopsy. EUS provides high-resolution local wall assessment. CT provides comprehensive anatomical staging. MRI can offer complementary soft-tissue characterization, while PET/CT may provide metabolic information in selected clinical circumstances.
For the radiologist, the most important task is to integrate these findings rather than interpret each examination in isolation.
For medical AI, the opportunity is similarly integrative. The future is unlikely to be defined solely by automated cancer detection. More meaningful applications may involve multimodal interpretation, tumor quantification, staging support, longitudinal assessment, treatment-response prediction, and integration with PACS, RIS, and EMR systems.
But the fundamental principle remains unchanged:
AI may assist the interpretation. It does not remove the responsibility to interpret the patient.
Clinical Risk & Diagnostic Insight
⚠️ Diagnostic
Risk Perspective
It highlights a broader issue in clinical radiology:
👉
Diagnostic miss risk in non-target regions
The gastric air bubble is frequently visible — yet rarely analyzed in detail.
This creates a systematic blind spot.
💰
Healthcare System Impact of Missed Findings
- Increased treatment cost due to advanced-stage disease
- Prolonged hospitalization and supportive care
- Higher utilization of oncology therapies
- Increased medico-legal exposure
In high-volume healthcare systems, even a small miss rate can translate into substantial cumulative cost and risk.
🧠
Workflow Reality: Why Misses Still Happen
- High daily case volume
- Cognitive load and fatigue
- Satisfaction of search bias
- Focus on primary indication
- Time constraints in reporting
👉 These
are system-level factors, not individual failure.
A realistic role of AI in this context includes:
- Flagging unexpected abnormalities outside the primary region
- Highlighting subtle density changes
- Providing secondary review in high-throughput environments
However, important limitations remain:
- False-positive alerts
- Workflow interruption
- Limited generalization across institutions
AI does not eliminate diagnostic responsibility — it redistributes attention.
⚠️ Clinical
Implementation Insight
- Integration into PACS workflow
- Clinically acceptable false-positive rate
- Clearly defined medico-legal responsibility
Without these, detection alone does not translate into improved outcomes.
🔎
Practical Takeaway for Radiology Practice
- Always review the gastric air bubble
- Assess the upper abdominal contour
- Question any unusual opacity below the diaphragm
- Avoid narrowing interpretation only to the lungs
The most important finding may lie outside the expected field.
📈 Future
Perspective: Imaging at Scale
This creates a growing need for:
- Structured reporting approaches
- AI-assisted triage systems
- Workflow-aware diagnostic support tools
The goal is not to replace radiologists — but to reduce blind spots in complex clinical environments.
⚠️ Radiology
Risk Alert
This case demonstrates how gastric cancer may appear outside the expected field of view.
Key Takeaways
A chest radiograph may unexpectedly reveal a gastric malignancy.
A round irregular opacity within the gastric air bubble warrants clinical correlation.
High-grade poorly differentiated gastric adenocarcinoma represents an aggressive histologic phenotype.
Histologic grade and TNM stage should not be conflated.
Endoscopy and biopsy establish the diagnosis.
CT plays a central role in staging.
EUS provides high-resolution local wall assessment.
MRI and PET/CT have complementary roles in selected patients.
Small peritoneal metastases may remain difficult to detect.
AI has potential applications in detection, staging, radiomics, and treatment-response prediction.
Clinical AI requires external validation, monitoring, governance, and human oversight.
Continue Learning
Gastric Cancer and Gastric Outlet Obstruction: CT Imaging Clues
Explore how CT identifies gastric enlargement, gastric wall abnormalities, obstruction, lymphadenopathy, and complications.
Read more: Gastric Enlargement Due to Gastric Outlet Obstruction: The Hidden Emergency Every Radiologist Should Recognize Early
Gastric Adenocarcinoma and Unusual Metastatic Spread
Learn how poorly differentiated gastric adenocarcinoma can present with an unusual metastatic pattern and why imaging may provide important clues to advanced disease.
Read more: Leptomeningeal Carcinomatosis from Gastric Adenocarcinoma: A Rare Culprit of Rapid Cognitive Decline in the Elderly
Gastric Intraluminal Masses: CT Differential Diagnosis
Review the characteristic CT appearance of trichobezoar and other intragastric mass-like lesions that may mimic gastric pathology.
Read more: How CT Detects Trichobezoar Before Life-Threatening Bowel Obstruction Occurs
Gastric Cancer and Gastric Outlet Obstruction: CT Imaging Clues
Explore how CT identifies gastric enlargement, gastric wall abnormalities, obstruction, lymphadenopathy, and complications.
Read more: Gastric Enlargement Due to Gastric Outlet Obstruction: The Hidden Emergency Every Radiologist Should Recognize Early
Gastric Adenocarcinoma and Unusual Metastatic Spread
Learn how poorly differentiated gastric adenocarcinoma can present with an unusual metastatic pattern and why imaging may provide important clues to advanced disease.
Read more: Leptomeningeal Carcinomatosis from Gastric Adenocarcinoma: A Rare Culprit of Rapid Cognitive Decline in the Elderly
Gastric Intraluminal Masses: CT Differential Diagnosis
Review the characteristic CT appearance of trichobezoar and other intragastric mass-like lesions that may mimic gastric pathology.
Read more: How CT Detects Trichobezoar Before Life-Threatening Bowel Obstruction Occurs
References
1. Polo JL, Porres JC. Gastric
Cancer in Chest Radiograph. N Engl J Med. 2017;376(1):73.
doi:10.1056/NEJMicm1603385.
2. Giandola T, Maino C,
Marrapodi G, Ratti M, Ragusi M, Bigiogera V, Talei Franzesi C, Corso R,
Ippolito D. Imaging in Gastric Cancer: Current Practice and Future
Perspectives. Diagnostics. 2023;13(7):1276. doi:10.3390/diagnostics13071276.
3. Smyth EC, Nilsson M,
Grabsch HI, van Grieken NCT, Lordick F. Gastric cancer. Lancet.
2020;396(10251):635–648. doi:10.1016/S0140-6736(20)31288-5.
4. Lordick F, Carneiro F,
Cascinu S, et al. Gastric cancer: ESMO Clinical Practice Guideline for
diagnosis, treatment and follow-up. Ann Oncol. 2022;33(10):1005–1020.
doi:10.1016/j.annonc.2022.07.004.
5. Ajani JA, D'Amico TA,
Bentrem DJ, et al. Gastric Cancer, Version 2.2025, NCCN Clinical Practice
Guidelines in Oncology. J Natl Compr Canc Netw. 2025;23(5):169–191.
doi:10.6004/jnccn.2025.0022.
6. Amin MB, Greene FL, Edge
SB, et al. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a
bridge from a population-based to a more “personalized” approach to cancer
staging. CA Cancer J Clin. 2017;67(2):93–99. doi:10.3322/caac.21388.
7. Brierley JD, Gospodarowicz
MK, Wittekind C, eds. TNM Classification of Malignant Tumours. 8th ed. Oxford,
UK: Wiley-Blackwell; 2017.
8. Japanese Gastric Cancer
Association. Japanese Gastric Cancer Treatment Guidelines 2021 (6th edition). Gastric
Cancer. 2023;26:1–25.
9. Washington K. 7th edition
of the AJCC cancer staging manual: stomach. Ann Surg Oncol.
2010;17:3077–3079. doi:10.1245/s10434-010-1362-z.
10. Degiuli M, De Manzoni G,
Di Leo A, et al. Gastric cancer: Current status of lymph node dissection. World
J Gastroenterol. 2016;22(10):2875–2893. doi:10.3748/wjg.v22.i10.2875.
11. Wagner AD, Lordick F,
Grabsch HI, et al. Multidisciplinary management of stage II–III gastric and
gastro-oesophageal junction cancer. Eur J Cancer. 2020;124:67–76.
doi:10.1016/j.ejca.2019.09.006.
12. Ychou M, Boige V, Pignon
JP, et al. Perioperative chemotherapy compared with surgery alone for
resectable gastroesophageal adenocarcinoma: FNCLCC/FFCD multicenter phase III
trial. J Clin Oncol. 2011;29(13):1715–1721.
doi:10.1200/JCO.2010.33.0597.
13. Bang YJ, Van Cutsem E,
Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus
chemotherapy alone for treatment of HER2-positive advanced gastric or
gastro-oesophageal junction cancer (ToGA). Lancet.
2010;376(9742):687–697. doi:10.1016/S0140-6736(10)61121-X.
14. Wagner AD, Syn NL, Moehler
M, et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst
Rev. 2017;8:CD004064. doi:10.1002/14651858.CD004064.pub4.
15. Mranda GM, Xue Y, Zhou XG,
et al. Revisiting the 8th AJCC system for gastric cancer: a review on
validations, nomograms, lymph nodes impact, and proposed modifications. Ann
Med Surg (Lond). 2022;75:103411. doi:10.1016/j.amsu.2022.103411.
Figure
source attribution
Figure 1 — Clinical case image
Polo JL, Porres JC. Gastric Cancer in Chest Radiograph. N Engl J Med. 2017;376:73. doi:10.1056/NEJMicm1603385.
Figures
2–6 — Educational CT images
Giandola
T, Maino C, Marrapodi G, et al. Imaging in Gastric Cancer: Current Practice
and Future Perspectives. Diagnostics. 2023;13(7):1276.
doi:10.3390/diagnostics13071276.
Medical Disclaimer
This article is intended for medical education and professional information. It does not provide individualized diagnosis, treatment recommendations, or medical advice. Imaging findings must be interpreted in the context of the patient's clinical history, laboratory findings, endoscopic findings, pathology, and multidisciplinary assessment. Treatment decisions should be made by qualified healthcare professionals based on current clinical guidelines and individual patient circumstances.
Comments
Post a Comment